HK1209054A1 - Laquinimod formulations without alkalizing agent - Google Patents
Laquinimod formulations without alkalizing agentInfo
- Publication number
- HK1209054A1 HK1209054A1 HK15109818.4A HK15109818A HK1209054A1 HK 1209054 A1 HK1209054 A1 HK 1209054A1 HK 15109818 A HK15109818 A HK 15109818A HK 1209054 A1 HK1209054 A1 HK 1209054A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- alkalizing agent
- laquinimod
- formulations
- laquinimod formulations
- alkalizing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670268P | 2012-07-11 | 2012-07-11 | |
PCT/US2013/049894 WO2014011750A1 (en) | 2012-07-11 | 2013-07-10 | Laquinimod formulations without alkalizing agent |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1209054A1 true HK1209054A1 (en) | 2016-03-24 |
Family
ID=49914501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15109818.4A HK1209054A1 (en) | 2012-07-11 | 2015-10-08 | Laquinimod formulations without alkalizing agent |
Country Status (19)
Country | Link |
---|---|
US (1) | US20140018386A1 (ja) |
EP (1) | EP2872141A4 (ja) |
JP (1) | JP2015527321A (ja) |
KR (1) | KR20150036553A (ja) |
CN (1) | CN104470519A (ja) |
AR (1) | AR091706A1 (ja) |
AU (1) | AU2013290274A1 (ja) |
BR (1) | BR112015000321A2 (ja) |
CA (1) | CA2873230A1 (ja) |
EA (1) | EA201590193A1 (ja) |
HK (1) | HK1209054A1 (ja) |
IL (1) | IL236229A0 (ja) |
MX (1) | MX2015000398A (ja) |
NZ (1) | NZ630241A (ja) |
SG (2) | SG10201700198VA (ja) |
TW (1) | TW201408299A (ja) |
UA (1) | UA115555C2 (ja) |
WO (1) | WO2014011750A1 (ja) |
ZA (1) | ZA201500287B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2977049A1 (en) | 2007-12-20 | 2016-01-27 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
KR20150091077A (ko) | 2012-11-07 | 2015-08-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드의 아민염 |
US9233927B2 (en) | 2013-03-14 | 2016-01-12 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
MX2016013944A (es) | 2014-04-29 | 2017-01-09 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis multiple recidivante-remitente (rrms) con un alto estado de discapacidad. |
CN107823168A (zh) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | 一种快速溶解的片剂及其制备方法 |
CN107823150A (zh) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | 一种可快速分散的片剂及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
CN101291911B (zh) * | 2005-10-19 | 2014-08-13 | 泰华制药工业有限公司 | 拉奎尼莫钠晶体及其制备方法 |
MX2008015808A (es) * | 2006-06-12 | 2009-02-17 | Teva Pharma | Preparaciones de laquinimod estable. |
EP2977049A1 (en) * | 2007-12-20 | 2016-01-27 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
US20120009226A1 (en) * | 2008-12-17 | 2012-01-12 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
EA201490378A1 (ru) * | 2011-07-28 | 2014-07-30 | Тева Фармасьютикал Индастриз Лтд. | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β |
-
2013
- 2013-07-08 AR ARP130102429 patent/AR091706A1/es unknown
- 2013-07-09 TW TW102124610A patent/TW201408299A/zh unknown
- 2013-07-10 SG SG10201700198VA patent/SG10201700198VA/en unknown
- 2013-07-10 SG SG11201407688QA patent/SG11201407688QA/en unknown
- 2013-07-10 WO PCT/US2013/049894 patent/WO2014011750A1/en active Application Filing
- 2013-07-10 CA CA2873230A patent/CA2873230A1/en not_active Abandoned
- 2013-07-10 US US13/938,733 patent/US20140018386A1/en not_active Abandoned
- 2013-07-10 EP EP13816725.9A patent/EP2872141A4/en not_active Withdrawn
- 2013-07-10 CN CN201380027660.2A patent/CN104470519A/zh active Pending
- 2013-07-10 MX MX2015000398A patent/MX2015000398A/es unknown
- 2013-07-10 EA EA201590193A patent/EA201590193A1/ru unknown
- 2013-07-10 JP JP2015521771A patent/JP2015527321A/ja active Pending
- 2013-07-10 BR BR112015000321A patent/BR112015000321A2/pt active Search and Examination
- 2013-07-10 AU AU2013290274A patent/AU2013290274A1/en not_active Abandoned
- 2013-07-10 NZ NZ630241A patent/NZ630241A/en not_active IP Right Cessation
- 2013-07-10 KR KR1020157003693A patent/KR20150036553A/ko not_active Application Discontinuation
- 2013-10-07 UA UAA201413984A patent/UA115555C2/uk unknown
-
2014
- 2014-12-14 IL IL236229A patent/IL236229A0/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00287A patent/ZA201500287B/en unknown
- 2015-10-08 HK HK15109818.4A patent/HK1209054A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014011750A1 (en) | 2014-01-16 |
NZ630241A (en) | 2017-09-29 |
SG11201407688QA (en) | 2014-12-30 |
MX2015000398A (es) | 2015-04-10 |
CA2873230A1 (en) | 2014-01-16 |
EA201590193A1 (ru) | 2015-04-30 |
AU2013290274A1 (en) | 2014-11-27 |
US20140018386A1 (en) | 2014-01-16 |
IL236229A0 (en) | 2015-01-29 |
UA115555C2 (uk) | 2017-11-27 |
BR112015000321A2 (pt) | 2017-06-27 |
KR20150036553A (ko) | 2015-04-07 |
TW201408299A (zh) | 2014-03-01 |
ZA201500287B (en) | 2016-10-26 |
SG10201700198VA (en) | 2017-02-27 |
EP2872141A1 (en) | 2015-05-20 |
WO2014011750A8 (en) | 2014-12-04 |
EP2872141A4 (en) | 2016-01-13 |
JP2015527321A (ja) | 2015-09-17 |
CN104470519A (zh) | 2015-03-25 |
AR091706A1 (es) | 2015-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212701A1 (zh) | 恩雜魯胺製劑 | |
TWI563077B (en) | Cleaning formulations | |
HK1203812A1 (en) | Novel pharmaceutical formulations | |
HK1209054A1 (en) | Laquinimod formulations without alkalizing agent | |
HK1205679A1 (en) | Nicotine formulation | |
PL2908835T3 (pl) | Stabilne formulacje | |
IL234747A0 (en) | Vascular formulations | |
HK1207290A1 (en) | Oral formulation | |
IL235988B (en) | Drug composition is based on genotype or phenotype | |
PL2908859T3 (pl) | Formulacje arypiprazolu | |
HK1209339A1 (en) | Pharmaceutical formulations | |
HK1202249A1 (en) | Vesicular formulations | |
GB201211406D0 (en) | Pharmaceutical formulations | |
GB201211403D0 (en) | Pharmaceutical formulations | |
IL234771A0 (en) | Nicotine formulation | |
GB201206178D0 (en) | Formulations |